Table 2.

Incidences and hazard ratios for risks of PE, PAOD, and DVT in recipients of various ADT treatment for prostate cancer.

	Event no	Person-years	Rate (per 1000 person-years)	Adjusted HR (95% CI)a
Outcome: DVT
Control	37	22811	1.62	Ref.
ADT overall	92	32021	2.87	2.11 (1.33–3.36)**
Surgical castration	2	1219	1.64	0.96 (0.23–4.02)
Anti-androgen	51	18209	2.80	2.17 (1.30–3.62)**
Chemical castration	39	12592	3.10	2.27 (1.32–3.89)**
GnRH agonist alone	4	2504	1.60	1.30 (0.45–3.77)
CAB	35	10089	3.47	2.53 (1.45–4.42)**
Total castration	41	13811	2.97	2.06 (1.23–3.46)**
Duration of chemical castration
≤180 days	5	1152	4.34	2.78 (1.00–7.72)*
181–720 days	17	5882	2.89	2.16 (1.12–4.17)*
>720 days	17	5558	3.06	2.29 (1.17–4.50)*
≤720 days	22	7034	3.13	2.28 (1.24–4.19)**
>720	17	5558	3.06	2.31 (1.17–4.53)*
Outcome: PE
Control	12	22896	0.52	Ref.
ADT overall	32	32158	1.00	2.10 (0.94–4.72)
Surgical castration	0	1230	0.00	NA
Anti-androgen	18	18295	0.98	2.25 (0.91–5.60)
Chemical castration	14	12634	1.11	2.51 (0.97–6.46)
GnRH agonist alone	0	2515	0.00	NA
CAB	14	10119	1.38	3.11 (1.19–8.16)*
Total castration	14	13863	1.01	2.07 (0.85–5.05)
Duration of chemical castration
≤180 days	1	1155	0.87	2.59 (0.30–22.2)
181–720 days	7	5902	1.19	3.27 (1.09–9.76)*
>720 days	6	5576	1.08	1.95 (0.61–6.22)
≤720 days	8	7058	1.13	3.16 (1.10–9.07)*
>720	6	5576	1.08	1.95 (0.61–6.19)
Outcome: PAOD
Control	16	22887	0.70	Ref.
ADT overall	33	32103	1.03	1.01 (0.53–1.92)
Surgical castration	0	1230	0.00	NA
Anti-androgen	22	18267	1.20	1.17 (0.59–2.34)
Chemical castration	11	12606	0.87	0.84 (0.38–1.89)
GnRH agonist alone	0	2515	0.00	NA
CAB	11	10092	1.09	1.01 (0.45–2.30)
Total castration	11	13836	0.80	0.78 (0.35–1.75)
Duration of chemical castration
≤180 days	1	1154	0.87	1.26 (0.15–10.3)
181–720 days	4	5894	0.68	0.71 (0.23–2.21)
>720 days	6	5558	1.08	0.91 (0.34–2.48)
≤720 days	5	7049	0.71	0.78 (0.27–2.21)
>720	6	5558	1.08	0.92 (0.34–2.49)

*p < 0.05; **p < 0.01.

^aAdjusted for all variables listed in Table 1.